Answers are grounded in this paper and cite their sources.
Neuroinflammation contributes to autoimmune and antibody-mediated neurological disorders, chronic neurodegenerative diseases, and acute cerebrovascular injury, although the initiating pathology, affected compartment, and temporal course differ among these conditions. The NLRP3 inflammasome links disturbances in ionic balance, organelle integrity, and cellular metabolism to caspase-1 activation, interleukin-1β and interleukin-18 maturation, gasdermin D-dependent membrane permeabilization, and pyroptosis. This review describes NLRP3 assembly, activation pathways, upstream regulation, and effector mechanisms in the nervous system and relates these processes to disease-specific pathology. Microglia and infiltrating myeloid cells are the most consistent sites of functional NLRP3 activity, whereas astrocytic, neuronal, oligodendroglial, and neurovascular responses occur in more restricted contexts. In autoimmune disorders of the central and peripheral nervous systems, NLRP3-associated signaling contributes to immune-cell recruitment, glial injury, and inflammatory demyelination. In Parkinson’s and Alzheimer’s diseases, pathological protein accumulation and mitochondrial or metabolic stress sustain inflammasome-associated inflammation. Ischemic and hemorrhagic stroke engage the pathway through damage-associated molecular pattern release, neurovascular injury, and cellular stress associated with ischemia, hemorrhage, and reperfusion. Human studies have mainly measured NLRP3-related transcripts, proteins, and downstream mediators in blood, cerebrospinal fluid, or tissue, whereas mechanistic and therapeutic findings derive largely from experimental models. Comparisons among experimental autoimmune encephalomyelitis, toxin- and protein-based neurodegeneration models, and different stroke paradigms show that NLRP3 involvement varies with the pathological construct, cellular target, disease stage, and intervention window. Direct NLRP3 inhibitors and indirect pathway modulators have attenuated inflammatory or pathological outcomes in selected models. In an open-label phase 1b study in Parkinson’s disease, NT-0796 achieved central nervous system exposure and altered peripheral and cerebrospinal fluid inflammatory markers, but clinical efficacy was not assessed. The contribution of NLRP3 to neurological inflammation is therefore disease-, cell-, model-, and stage-dependent. Clinical translation requires identification of the relevant human cell populations and treatment windows, confirmation of central target modulation, and biomarkers for patient selection and treatment monitoring.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: